# EDGAR Filing Document

**Accession Number:** 0001779578
**File Stem:** 0001104659-23-022871
**Filing Date:** 2023-2
**Character Count:** 6810
**Document Hash:** 4e8f7120eb9fcbc8c5108881032f2c26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-022871.hdr.sgml**: 20230216

**ACCESSION NUMBER**: 0001104659-23-022871

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230216

**FILED AS OF DATE**: 20230216

**DATE AS OF CHANGE**: 20230216

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Qilian International Holding Group Ltd
- **CENTRAL INDEX KEY:** 0001779578
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39805
- **FILM NUMBER:** 23639282

**BUSINESS ADDRESS:**
- **STREET 1:** JIUQUAN ECONOMIC AND TECHNOLOGICAL
- **STREET 2:** DEVELOPMENT ZONE
- **CITY:** JIUQUAN, GANSU PROVINCE
- **STATE:** F4
- **ZIP:** 735001
- **BUSINESS PHONE:** 86-0937-2689523

**MAIL ADDRESS:**
- **STREET 1:** JIUQUAN ECONOMIC AND TECHNOLOGICAL
- **STREET 2:** DEVELOPMENT ZONE
- **CITY:** JIUQUAN, GANSU PROVINCE
- **STATE:** F4
- **ZIP:** 735001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February 2023

**QILIAN INTERNATIONAL HOLDING GROUP LTD**

(Exact name of registrant as specified in its charter)

**Jiuquan Economic and Technological Development Zone**

**Jiuquan City, Gansu Province, 735000<br> +86-028-64775180**

**(Address of Principal Executive Office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

**Announcement of Special Cash Dividends to Shareholders** 

On February 16, 2023, Qilian International Holding Group Ltd (the "**Company**") issued a press release to announce that its board of directors had declared a one-time special cash dividend of $0.05 per ordinary shares, payable on or about March 6, 2023, to shareholders of record as of February 28, 2023. The press release is furnished as Exhibit 99.1 to this Current Report on Form 6-K.

The information contained in this Current Report and the attached Exhibit 99.1 is furnished to and not filed with the Securities and Exchange Commission, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.

**Exhibit**

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit** |
| [99.1](tm236761d1_ex99-1.htm) | [Press Release dated February 16, 2023](tm236761d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Qilian International Holding Group Ltd** | **Qilian International Holding Group Ltd** |
| Date: February 16, 2023 | By: | */s/ Zhanchang Xin* |
|  | Name: | Zhanchang Xin |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders**

Jiuquan, China, February 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023.

"Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company.

**About Qilian International Holding Group Ltd**

Qilian International Holding Group Ltd, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at http://ir.qlsyy.net.

**Forward-Looking Statements**

*This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; products demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China; the COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.*